Coya Therapeutics Inc., a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function in neurodegenerative disorders, announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug $(IND)$ application for COYA 302 for the treatment of frontotemporal dementia (FTD). This acceptance enables Coya to advance COYA 302 into clinical trials for FTD, a disease with significant unmet medical needs and no approved disease-modifying treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105080790) on January 05, 2026, and is solely responsible for the information contained therein.